CureVac’s flu vaccine to undergo ‘targeted optimisation’ for certain strains

2024-04-04
Firstwordpharma
疫苗临床结果临床2期信使RNA免疫疗法
CureVac reported a hit and a miss for its multivalent seasonal flu vaccine on Thursday. While the candidate, which is partnered with GSK, boosted antibody titers against influenza A strains, the immune responses fell short against the B strains.
The interim data was from the second part of a Phase I/II study that enrolled 480 healthy younger adults ages 18 to 64, and the same number of older adults ages 65 to 85. Participants received one of three different dose levels of CureVac’s vaccine, which was developed with the biotech’s second-generation mRNA backbone, and immune responses were compared with approved seasonal flu vaccines.
In both age groups, geometric mean antibody titers generated by the vaccine candidate against influenza A strains “numerically exceeded” titers of the comparator vaccines “across all tested dose levels.” However, against influenza B strains, titers were lower across age groups and doses.
According to the company, “targeted optimisations to further improve immune responses against influenza B strains will be tested in an additional Phase II study.”
"Results regarding influenza A strains were strong,” CureVac CEO Myriam Mendila said. “Immunogenicity for B strains was in line with our expectations also in view of other initial mRNA-based clinical flu development programs. We are confident that planned optimizations will improve performance against these historically challenging influenza strains."
The company said its vaccine candidate had an “acceptable” safety and tolerability profile, and the majority of reported adverse events were either grade 1 or grade 2 within a week of dosing.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
-
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。